Related Experiment Videos
Haemophilus influenzae type B conjugate vaccines
R W Force1, R A Lugo, M C Nahata
1College of Pharmacy, Ohio State University, Columbus 43210.
The Annals of Pharmacotherapy
|November 1, 1992
Summary
New Haemophilus influenzae type b (Hib) conjugate vaccines offer superior efficacy and immunogenicity in children, significantly reducing invasive Hib disease incidence. These vaccines are recommended for infants as young as two months.
Area of Science:
- Immunology
- Epidemiology
- Vaccinology
Background:
- Haemophilus influenzae type b (Hib) causes serious invasive disease in young children.
- The original Hib vaccine had limitations, particularly in children under two years.
Purpose of the Study:
- Review Hib disease epidemiology.
- Evaluate Hib vaccine efficacy and administration.
- Compare older and newer Hib vaccines.
Main Methods:
- Literature review using MEDLINE database.
- Analysis of cited references from published articles.
- Review of studies on Hib disease epidemiology and vaccine efficacy/immunogenicity.
Main Results:
- Hib infection leads to significant childhood morbidity and mortality.
- Older Hib vaccine was ineffective in infants under two.
- New Hib conjugate vaccines demonstrate superior efficacy and immunogenicity.
- Licensed Hib conjugate vaccines protect children from two months of age.
Conclusions:
- New Hib conjugate vaccines provide excellent efficacy.
- Recommended use of Hib conjugate vaccines can reduce invasive disease incidence and sequelae.